Market Trends

Many pharmaceutical companies are focusing on lung cancer therapies, but recent research highlights that liver cancer may present a larger opportunity. PD-1/VEGF bispecific antibodies are expected to be effective by simultaneously blocking immune suppression and angiogenesis, thereby inhibiting tumor growth.

Technical Background

Bispecific antibodies that target both PD-1 (Programmed Death‑1) and VEGF (Vascular Endothelial Growth Factor) are gaining scientific support for their ability to block both pathways concurrently, potentially enhancing therapeutic efficacy. Liver cancer is characterized by robust angiogenesis, making VEGF inhibition particularly critical.

Corporate Strategy

Pharmaceutical companies are seeking new growth drivers as the lung‑cancer market becomes saturated and competition intensifies. Consequently, allocating substantial capital to PD-1/VEGF bispecific antibody pipelines targeting liver cancer has emerged as a recent trend. However, debates over target suitability are raising concerns about investment risk.

Investment & Research Implications

Clinical data for liver‑cancer therapies remain early-stage, creating considerable uncertainty, but successful outcomes could generate a market worth several tens of billions of dollars. Conversely, an inappropriate target choice could significantly impede the recovery of R&D expenditures. Investors therefore need to closely monitor pipeline progress and clinical results.